Ribavirin - Generic Drug Details

What are the generic drug sources for ribavirin and what is the scope of freedom to operate?

Ribavirin is the generic ingredient in five branded drugs marketed by Merck Sharp Dohme, Chartwell Rx, Aurobindo Pharma, Teva, Zydus Pharms Usa, Bausch, Schering, Roche, Beximco Pharms Usa, Heritage Pharma Avet, and Sandoz, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.

Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for ribavirin

US Patents:	0
Tradenames:	5
Applicants:	12
NDAs:	16
Drug Master File Entries:	15
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	111
Clinical Trials:	1,036
Drug Prices:	Drug price trends for ribavirin
What excipients (inactive ingredients) are in ribavirin?	ribavirin excipients list
DailyMed Link:	ribavirin at DailyMed

See drug prices for ribavirin

Recent Clinical Trials for ribavirin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Liverpool School of Tropical Medicine	PHASE2
Khyber Medical University Peshawar	PHASE3
University of Oxford	PHASE2

See all ribavirin clinical trials

Generic filers with tentative approvals for RIBAVIRIN

Applicant	Application No.	Strength	Dosage Form
		40MG/ML	SOLUTION; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ribavirin

Drug Class

Nucleoside Analog Antiviral

Medical Subject Heading (MeSH) Categories for ribavirin

Antimetabolites

Antiviral Agents

Anatomical Therapeutic Chemical (ATC) Classes for ribavirin

J05AP	Antivirals for treatment of HCV infections
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for RIBAVIRIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIRAZOLE	for Inhalation Solution	ribavirin	6 gm/vial	018859	1	2014-05-22

US Patents and Regulatory Information for ribavirin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	REBETOL	ribavirin	SOLUTION;ORAL	021546-001	Jul 29, 2003		DISCN	Yes	No
Chartwell Rx	RIBAVIRIN	ribavirin	FOR SOLUTION;INHALATION	207366-001	Oct 6, 2016		DISCN	No	No
Chartwell Rx	RIBAVIRIN	ribavirin	TABLET;ORAL	077456-001	Dec 5, 2005		DISCN	No	No
Beximco Pharms Usa	RIBAVIRIN	ribavirin	TABLET;ORAL	202546-001	Aug 12, 2014		DISCN	No	No

Expired US Patents for ribavirin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-001	Jun 3, 1998	4,211,771
Bausch	VIRAZOLE	ribavirin	FOR SOLUTION;INHALATION	018859-001	Dec 31, 1985	6,150,337
Bausch	VIRAZOLE	ribavirin	FOR SOLUTION;INHALATION	018859-001	Dec 31, 1985	4,211,771
Bausch	VIRAZOLE	ribavirin	FOR SOLUTION;INHALATION	018859-001	Dec 31, 1985	RE29835

EU/EMA Drug Approvals for ribavirin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp and Dohme B.V	Rebetol	ribavirin	EMEA/H/C/000246Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.	Withdrawn	no	no	no	1999-05-06
Teva B.V.	Ribavirin Teva Pharma B.V.	ribavirin	EMEA/H/C/001064Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).	Withdrawn	yes	no	no	2009-07-01
Teva B.V.	Ribavirin Teva	ribavirin	EMEA/H/C/001018Ribavirin Teva is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patients Adult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA.Paediatric patients (children 3 years of age and older and adolescents) Ribavirin Teva is indicated, in a combination regimen with interferon alfa­2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis.Previous treatment failure patientsAdult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.	Withdrawn	yes	no	no	2009-03-31
Mylan S.A.S	Ribavirin Mylan (previously Ribavirin Three Rivers)	ribavirin	EMEA/H/C/001185Ribavirin Mylan is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with interferon alfa-2b (adults, children (three years of age and older) and adolescents). Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).Please refer also to the interferon alfa-2b summary of product characteristics (SmPC) for prescribing information particular to that product.Naïve patientsAdult patientsRibavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for serum hepatitis-C-virus (HCV) RNA.Children and adolescentsRibavirin Mylan is indicated, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents three years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for serum HCV RNA. When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case-by-case basis (see section 4.4).Previously treatment-failure patientsAdult patientsRibavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.	Withdrawn	yes	no	no	2010-06-10

Ribavirin Market Dynamics, Financial Trajectory, Patent Exclusivity, and Generic Competition

Last updated: August 24, 2026

Ribavirin is a mature, low-revenue generic antiviral with limited commercial growth prospects. Its historical value came from combination therapy for hepatitis C virus (HCV), but direct-acting antivirals have largely displaced it. Current demand is concentrated in narrow indications, including selected respiratory syncytial virus (RSV) cases, certain viral hemorrhagic fevers under specialist protocols, and occasional combination regimens for difficult-to-treat viral infections. The U.S. product market has no meaningful brand-driven pricing power, no active composition-of-matter exclusivity, and limited incentive for new entrants.

What is ribavirin and how is it used?

Ribavirin is a synthetic guanosine nucleoside analogue with broad antiviral activity. It is marketed in oral capsules, tablets, oral solution, and inhalation formulations, depending on jurisdiction and product availability.

Attribute	Ribavirin
Active ingredient	Ribavirin
Drug class	Nucleoside analogue antiviral
Primary historical use	Combination treatment for chronic HCV
Current U.S. uses	Limited combination use for HCV; inhaled therapy for selected hospitalized infants and young children with severe RSV disease
Major manufacturers	Multiple generic manufacturers; historical brands included Rebetol, Copegus and Virazole
FDA status	FDA-approved products remain listed for specific formulations and indications, subject to commercial availability
Regulatory category	Small-molecule drug, not a biologic
Biosimilar exposure	None
Generic exposure	Extensive
Patent position	Foundational exclusivity expired; residual product or method patents are not commercially central

For HCV, ribavirin was historically administered with interferon or pegylated interferon. Modern HCV treatment relies on oral direct-acting antiviral combinations with materially higher cure rates, shorter treatment periods and better tolerability. The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America now recommend highly effective direct-acting antiviral regimens for most patients, limiting ribavirin to selected situations such as certain treatment failures or difficult clinical profiles. [1]

Ribavirin remains relevant in RSV because aerosolized Virazole is approved for use in hospitalized infants and young children with severe lower respiratory tract RSV infection. Its use is restricted by administration complexity, occupational exposure concerns, uncertain incremental benefit in some patient groups and the availability of supportive care. [2]

When did ribavirin lose exclusivity?

Ribavirin lost practical market exclusivity decades ago. Its active ingredient and core antiviral use were disclosed in patents filed in the 1970s, and the principal patent estate is no longer capable of supporting branded market protection in the United States.

The commercial sequence was:

Period	Market event	Financial effect
1970s-1980s	Original discovery, development and regulatory approvals	Created the initial branded market
1990s	Expansion in chronic HCV combination therapy	Increased volume and brand value
2000s	Rebetol, Copegus and Virazole were commercial reference products	Brand competition and formulation differentiation
2011-2015	First-generation HCV direct-acting antivirals entered the market	Reduced interferon-based treatment demand
2014 onward	All-oral HCV regimens expanded rapidly	Accelerated displacement of ribavirin in HCV
Current market	Generic, indication-specific demand	Low pricing and fragmented revenue

The core ribavirin molecule does not have meaningful remaining patent exclusivity in the United States. Any remaining enforceable rights would more likely relate to a particular formulation, delivery system, dosing regimen or combination treatment rather than the active ingredient itself. The FDA Orange Book is the controlling source for current patent listings associated with approved prescription products. [3]

What is the FDA and Orange Book status of ribavirin?

Ribavirin has had several FDA-approved products and formulations. Regulatory status varies by product and manufacturer because individual applications may be active, discontinued, or commercially unavailable even when the drug remains approved.

Oral ribavirin

Oral capsules, tablets and oral solution have been approved primarily for use in combination with interferon-based therapies or other antiviral regimens. The clinical importance of oral ribavirin declined sharply after the arrival of direct-acting antivirals.

The main FDA regulatory issues are:

• Ribavirin is not adequate as monotherapy for chronic HCV.
• It carries substantial teratogenic and embryocidal risk.
• Hemolytic anemia is a major dose-limiting toxicity.
• Renal impairment can materially increase exposure and toxicity.
• Treatment requires contraception controls and laboratory monitoring.
• Product labeling is tied to the approved combination regimen and patient population.

Inhaled ribavirin

Virazole is a lyophilized ribavirin product administered through a small-particle aerosol generator. The formulation has a distinct delivery system and clinical-use profile. Its commercial market is much narrower than the former oral HCV market.

Inhaled administration creates practical barriers:

• Specialized equipment is required.
• Administration can be prolonged and resource intensive.
• Health-care workers may face exposure concerns.
• Hospital protocols determine use.
• Demand is seasonal and concentrated among pediatric centers.

Orange Book analysis should distinguish active approved products from discontinued products and should not treat every historical brand listing as a current commercial competitor. [3]

How many patents cover ribavirin?

No current U.S. patent estate creates broad protection around ribavirin as an active pharmaceutical ingredient. The commercial patent count is therefore less important than the status of individual product claims.

Potential patent categories include:

Patent category	Relevance to ribavirin
Composition of matter	Expired or commercially irrelevant
Salt or crystal form	Limited relevance because ribavirin is an old, widely available molecule
Oral formulation	Possible historical or product-specific protection; generally weak against established generics
Inhalation formulation	More relevant because the delivery platform and administration process are specialized
Combination therapy	Historically important in HCV; reduced commercial value after DAA displacement
Method of treatment	Possible jurisdiction-specific claims; typically narrow and vulnerable to design-around
Manufacturing process	Potentially relevant for cost and quality control, but not a broad market barrier

Ribavirin's patent strength is low for oral products and modestly higher for inhaled delivery systems. Even where formulation or method claims exist, they do not restore the economic position that ribavirin held during the interferon-based HCV era.

Which companies are challenging ribavirin patents?

No major current Paragraph IV litigation campaign is central to the ribavirin market. The reason is economic: the product is already generic, the active ingredient is old, and the remaining addressable market is small.

Abbreviated new drug application applicants can rely on:

• Paragraph I certifications where no relevant patent is listed.
• Paragraph II certifications where listed patents have expired.
• Paragraph III certifications with launch after patent expiration.
• Paragraph IV certifications where an applicant asserts that a listed patent is invalid, unenforceable or not infringed.

For ribavirin, the expected value of a Paragraph IV challenge is limited because:

1. Generic products already exist.
2. Oral HCV demand has contracted.
3. Inhaled RSV demand is narrow and institutionally concentrated.
4. Litigation costs can exceed the value of market entry.
5. Product-specific patents, if any, generally do not cover the entire ribavirin market.

There is no comparable patent litigation profile to high-value products such as major HCV direct-acting antivirals, oncology drugs or biologics.

What is the market size and financial trajectory for ribavirin?

A single reliable global ribavirin revenue figure is not publicly reported because sales are divided among multiple generic companies, hospital suppliers and regional distributors. Manufacturers generally do not disclose ribavirin revenue separately in annual reports.

The financial trajectory is nevertheless clear:

Market driver	Direction	Effect on ribavirin
HCV treatment volume	Down	Structural erosion
Use with interferon	Down sharply	Loss of historical demand
Use with modern DAAs	Limited	Residual niche demand
RSV inhalation use	Stable to episodic	Supports a small hospital market
Generic competition	High	Price compression
Manufacturing complexity	Higher for aerosol products	Supports some supplier differentiation
Public-health demand	Variable	Can create temporary spikes
New clinical development	Minimal	No meaningful growth catalyst

Ribavirin's peak commercial value occurred when it was a core component of chronic HCV treatment. That market supported branded products and premium pricing. The introduction of sofosbuvir-based and other DAA regimens shifted treatment economics toward shorter, better-tolerated oral combinations. Gilead's HCV franchise illustrates the broader market transition: the company's HCV product revenue rose rapidly after Sovaldi and Harvoni launched, while the therapeutic role of interferon and ribavirin declined. [4]

The remaining market is primarily maintenance revenue rather than growth revenue. Demand can increase temporarily during severe RSV seasons or when clinicians use ribavirin under specialist protocols, but these events do not create a durable expansion cycle.

How does ribavirin compare with modern HCV antivirals?

Ribavirin is commercially disadvantaged on efficacy, tolerability, convenience and reimbursement.

Factor	Ribavirin	Modern direct-acting antivirals
Treatment role	Adjunct or fallback therapy	Primary curative therapy
Administration	Oral, with inhaled formulation for RSV	Oral fixed-dose combinations
Treatment duration	Often longer and regimen-dependent	Commonly 8-12 weeks, depending on regimen
Major toxicity	Hemolytic anemia, teratogenicity	Generally better tolerated
Monitoring burden	High	Lower
Patent position	Expired and generic	Some products retain or retained extensive protection
Pricing	Low generic pricing	Historically high branded pricing, later reduced by competition
Commercial outlook	Stable to declining niche	Larger, but increasingly competitive mature market

Ribavirin can still have clinical value when resistance, prior treatment failure, decompensated disease or other factors limit standard DAA use. Those cases are too narrow to reverse its financial decline.

What formulation patents protect ribavirin?

The most commercially relevant formulation issue is inhaled ribavirin. Aerosol delivery depends on particle generation, concentration, administration equipment and hospital workflow. These factors can create practical differentiation even without strong patent protection.

Oral ribavirin has limited formulation-based defensibility. Capsules, tablets and oral solutions are technically established dosage forms. Generic manufacturers can often enter without reproducing a proprietary delivery platform.

A formulation strategy could still create value if it improves:

• Pediatric dosing accuracy.
• Renal-dose flexibility.
• Stability and shelf life.
• Aerosol generation.
• Occupational exposure controls.
• Administration time.
• Compatibility with hospital respiratory equipment.

Such improvements would face a small addressable market and a high burden of demonstrating clinical or operational benefit.

What generic entry risks exist for ribavirin?

Generic entry risk is already realized rather than prospective. The key commercial risk is ongoing price erosion and supplier substitution.

Oral products

Oral ribavirin has high generic substitution risk. Buyers can switch among manufacturers with limited clinical disruption, subject to supply continuity and product-specific availability. Contracting and wholesaler purchasing power place pressure on net prices.

Inhaled products

Inhaled ribavirin has a higher operational barrier because hospitals may need specialized equipment, trained personnel and established treatment protocols. That barrier is commercial rather than necessarily patent-based.

The main risks are:

• Hospital formulary replacement.
• Supply interruptions.
• Low-volume manufacturing withdrawals.
• Seasonal demand volatility.
• Regulatory scrutiny of aerosol administration.
• Substitution with supportive care or alternative clinical approaches.

The market can therefore experience shortage risk despite weak patent protection. A small number of suppliers may remain active because low volume discourages entry, creating a supply problem rather than a strong pricing opportunity.

What licensing deals and partnerships affect ribavirin?

Ribavirin has no prominent current licensing transaction comparable to the major HCV licensing agreements involving nucleotide polymerase inhibitors or protease inhibitors. Historical commercial arrangements supported branded products and HCV combination regimens, but the central strategic value of those deals diminished after DAA adoption.

The current partnership landscape is more likely to involve:

• Hospital distribution agreements.
• Generic manufacturing and supply contracts.
• Regional registration rights.
• Contract manufacturing.
• Public-health procurement.
• Specialized respiratory-drug distribution.

No major pharmaceutical company is publicly positioning ribavirin as a strategic growth asset. Licensing value is therefore limited unless tied to a specialized formulation, a constrained geography or a broader antiviral platform.

What patent litigation affects ribavirin?

Ribavirin does not have a current litigation profile that materially affects its global commercial outlook. Past disputes involving HCV treatment patents generally centered on combination partners, DAA compounds or formulation technologies rather than on the core ribavirin molecule.

For investors and business-development teams, the relevant legal conclusion is that ribavirin is not a patent-driven market. Competitive outcomes depend more on:

• FDA approval status.
• Product availability.
• Hospital purchasing.
• Manufacturing economics.
• Supply reliability.
• Clinical guideline relevance.
• Reimbursement and procurement policy.

What is the geographic coverage of ribavirin demand?

Ribavirin remains available in multiple countries, but commercial demand differs by indication and health-system structure.

Geography	Main commercial characteristics
United States	Generic oral market and limited inhaled RSV use; highly mature
Europe	HCV use largely displaced by DAAs; national procurement and product availability vary
Middle East and Africa	Potential residual use where DAA access is constrained, although availability and guidelines differ
Latin America	Generic use persists in selected markets; pricing is procurement-driven
Asia-Pacific	Mixed demand, with country-specific HCV access and regulatory conditions
Low- and middle-income markets	Possible use where older antiviral protocols remain economically relevant

Geographic demand should not be inferred solely from disease prevalence. Ribavirin use depends on access to DAAs, local treatment guidelines, procurement budgets, diagnostic infrastructure and registration status.

How strong is the ribavirin patent estate?

The estate is weak from a life-cycle-management perspective.

Criterion	Assessment
Core molecule protection	Expired
Broad HCV treatment protection	Expired or commercially obsolete
Oral formulation protection	Low
Inhaled formulation protection	Low to moderate, depending on jurisdiction and claim scope
Manufacturing barriers	Moderate for specialized inhalation products
Generic challenge exposure	High
Ability to support premium pricing	Very low
Probability of major exclusivity extension	Low

Ribavirin's remaining defensibility is operational. A supplier with reliable inhalation manufacturing, regulatory approvals and hospital relationships may retain share despite the absence of broad patent protection.

What is the outlook for ribavirin revenue?

The base-case outlook is continued decline or low-level stabilization, not renewed expansion.

Revenue should remain concentrated in:

• Inhaled RSV treatment.
• Specialist HCV salvage regimens.
• Markets with constrained DAA access.
• Selected off-label or protocol-driven antiviral applications.
• Government or hospital procurement events.

Potential upside from new antiviral indications is limited. Ribavirin has been investigated for multiple viral diseases, including coronaviruses and viral hemorrhagic fevers, but investigation or protocol use does not equal FDA approval or predictable commercial demand. The FDA has not approved ribavirin as a general treatment for COVID-19. [5]

The principal downside risks are continued DAA penetration, reduced interferon use, generic price erosion, product discontinuation and hospital substitution. Supply shortages could produce temporary price increases, but they would not establish durable market growth.

Key Takeaways

• Ribavirin is a mature generic antiviral with no meaningful composition-of-matter exclusivity.
• HCV displacement by direct-acting antivirals caused the major long-term revenue decline.
• Current demand is concentrated in inhaled RSV treatment and narrow specialist indications.
• Oral ribavirin faces extensive generic competition and low pricing power.
• Inhaled ribavirin has greater operational complexity but only limited commercial defensibility.
• No major current Paragraph IV campaign or patent litigation materially shapes the market.
• Manufacturers do not generally report ribavirin revenue separately, preventing a reliable single global market-size figure.
• The financial outlook is stable-to-declining niche revenue, with episodic demand driven by RSV seasons and regional access conditions.
• Licensing value is limited and is more likely to arise from formulation, manufacturing or distribution arrangements than from the active ingredient.

FAQs

Is ribavirin still commercially relevant after the decline of hepatitis C treatment?

Yes, but only in narrow segments. It retains use in selected HCV combination regimens and in specialized RSV treatment, while its former role in routine HCV therapy has largely disappeared.

Does ribavirin have biosimilar competition?

No. Ribavirin is a chemically synthesized small-molecule drug, so competition occurs through generic drugs rather than biosimilars.

Can a generic company obtain a meaningful ribavirin price premium?

Usually not for oral products. A supplier may obtain better economics for inhaled ribavirin if it has reliable equipment, hospital contracts and limited competition, but the market remains small.

Is ribavirin approved for COVID-19 in the United States?

No. Ribavirin has been studied or used in selected investigational and protocol settings, but it is not FDA-approved as a general COVID-19 treatment. [5]

What is the most important commercial barrier to entering inhaled ribavirin?

The primary barriers are low market volume, specialized aerosol delivery requirements, hospital workflow integration and uncertain demand. These barriers are more operational and economic than patent-based.

References

1. American Association for the Study of Liver Diseases & Infectious Diseases Society of America. (2024). HCV guidance: Recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org/

2. U.S. Food and Drug Administration. (2019). Virazole (ribavirin) inhalation solution prescribing information. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. Gilead Sciences, Inc. (2016). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov/

5. U.S. Food and Drug Administration. (2024). Coronavirus disease 2019 (COVID-19): Drugs and biologics. https://www.fda.gov/------------------------------------------------------------------------